ERAS-801 for Glioblastoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
GlioblastomaERAS-801 - Drug
Eligibility
18 - 99
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the safety and effectiveness of a new drug, ERAS-801, for people with a certain type of brain tumor.

Eligible Conditions
  • Glioblastoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 7 Secondary · Reporting Duration: Assessed up to 24 months from time of first dose

Month 24
Adverse Events
Duration of Response (DOR)
Objective Response Rate (ORR)
Time to Response (TTR)
Day 29
Area under the curve
Dose Limiting Toxicities (DLT)
Half-life
Maximum Tolerated Dose (MTD)
Plasma concentration (Cmax)
Recommended Dose (RD)
Time to achieve Cmax (Tmax)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Dose Escalation (Part 1)
1 of 2
Dose Expansion (Part 2)
1 of 2

Experimental Treatment

90 Total Participants · 2 Treatment Groups

Primary Treatment: ERAS-801 · No Placebo Group · Phase 1

Dose Escalation (Part 1)
Drug
Experimental Group · 1 Intervention: ERAS-801 · Intervention Types: Drug
Dose Expansion (Part 2)
Drug
Experimental Group · 1 Intervention: ERAS-801 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessed up to 24 months from time of first dose

Who is running the clinical trial?

Erasca, Inc.Lead Sponsor
5 Previous Clinical Trials
800 Total Patients Enrolled
Sachin Pai, M.D.Study DirectorMedical Director

Eligibility Criteria

Age 18 - 99 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021 criteria.
You have normal organ function.
You are willing to comply with all protocol-required visits, assessments, and procedures.

Who else is applying?

What state do they live in?
Florida100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%